From Medicineworld.org: Arthritis Drug Effective for Depression
Cancer blog: I manage the cancer blog with lots of help and support form other bloggers. Through this cancer blog my friends and I try to bring stories of hope for patients with cancer. The cancer blog often republishes important blog posts from other cancer related blogs at Medicineworld.org. If you are searching for a blog that covers wide variety of cancer topics, this may be the one for you.
Breast cancer blog: Breast cancer blog is run by Emily and other bloggers and they bring you the latest stories, news and events that are related to breast cancer. Increasing awareness about breast cancer among women and in the general population is the main goal of this breast cancer blog.
Lung cancer blog: Lung cancer blog is managed by Scott with the help of other bloggers. Through this blog Scott and his friends constantly remind the readers about the dangers of smoking. It's a never-ending struggle against this miserable disease with which a social stigma of smoking is associated.
Colon cancer blog: Colon cancer blog is run by Sue and other bloggers. Sue brings a personal touch to the colon cancer blog since her mother died of colon cancer few years ago. She writes about stories, research news and advances in treatment related to colon cancer.
Prostate cancer blog: Prostate cancer is the most common cancer among American men. American Cancer Society estimates that over 230,000 new cases of prostate cancer occur in the United state every year. This important blog about prostate cancer is run by Mark and other bloggers. This blog brings news, stories, and other personal observations related to prostate cancer.
Medicineworld.org publishes a diabetes watch blog and this blog is run by JoAnn other bloggers. This diabetes watch blog brings you the latest in the field of diabetes. This includes personal stories, advances in diagnosis and treatment, and other observations about diabetes. Improving awareness about diabetes is an important mission of this group.
Arthritis Drug Effective for Depression
High concentrations of pro-inflammatory substances called cytokines, such as tumor necrosis factor-alpha (TNF-alpha), have been associated with major depression. According to Ranga Krishnan, M.D., the study author based at Duke, scientists have long hypothesized that reducing the effects of the cytokines may reverse depressive symptoms. Until now, no research team has examined the effects of a tumor necrosis factor receptor on depression in humans.
The phase III clinical trial was primarily designed to test the effectiveness of etanercept in improving the clinical symptoms of psoriasis, a chronic skin disease characterized by silvery, scaling bumps and raised patches of very dry skin. In severe cases, people can experience joint pain similar to that of rheumatoid arthritis. Psoriasis sufferers frequently experience problems with both depression and fatigue as a result of their disease.
"It has been shown that when you are sick or depressed, tumor necrosis factor concentration increases," said Krishnan, chief of psychiatry and behavioral sciences at Duke. "When TNF-alpha goes up, the symptoms are very similar to what is termed 'sickness behavior' and prior studies have shown that when a person is depressed, TNF-alpha levels are increased in blood".
The team wanted to determine whether etanercept would have any effect on the symptoms of depression that are so common among people with psoriasis.
The research team followed 618 study participants at 39 study sites in the randomized, double-blinded study. Participants received either 50 milligram twice-weekly subcutaneous injections of etanercept or matching placebo for a period of 12 weeks (placebo =307; etanercept =311), which constituted the placebo-controlled portion of the study. Subsequently, the participants were followed for 84 weeks during which all the participants received etanercept and knew it.
The scientists measured responses using the psoriasis area and severity index score (PASI), the dermatology life quality index, the functional assessment of chronic illness treatment fatigue scale, the Hamilton rating scale for depression (Ham-D) and the Beck depression inventory (BDI).
The scientists found that nearly half (47 percent) of participants achieved 75 percent or greater improvement in their clinical symptoms of psoriasis at week 12 while taking etanercept, compared to five percent of those on placebo having the same effect.
Notably, scientists found significant improvements on the BDI in the etanercept group in feelings of guilt, irritability, interest, appearance, work, sleep and sexual symptoms, compared with those receiving placebo. Ham-D scores for those receiving the etanercept showed improvements to insomnia, work, hypochondriasis and sexual problems when compared to the placebo group.
The etanercept group also showed lower levels of fatigue, with the improvement strongly correlated to improvements in joint and skin pain due to psoriasis, according to the researchers. Improvement in depression levels could not be correlated to improvement in those symptoms. However, the scientists point out that the study was not designed to detect the effect of etanercept on primary depression.
"While depression scores improved, we cannot be sure why," Krishnan said. "Our next step is to run this type of trial in people who have depression but not psoriasis. At this point, no one should run to their doctor and ask for this drug for depression. However, the science is very exciting to us".
The team's work is an important first look in humans at how a TNF antibody could improve secondary symptoms of depression, said Krishnan. Further research will unveil more clues to how TNF receptors work in the brain and may eventually lead to improved therapys for depression.
Krishan's work on this trial was supported by Amgen, but he holds no financial interest in the company or etanercept. Funding for the study was provided by Amgen. The primary study was designed by Immunex, the company responsible for developing etanercept. Amgen acquired Immunex in 2002.
Other authors on the study include Stephen Tyring, MD, University of Texas Health Science Center at Houston; Alice Gottlieb, MD, UMDNJ-Robert Wood Johnson Medical School; Kim Papp, MD, University of Western Ontario, London, Ontario and Probity Medical Research, Waterloo, Canada; Ken Gordon, MD, Evanston Northwestern Healthcare - Skokie, Ill.; David Cella, Ph.D., Evanston Northwestern Healthcare - Evanston, Ill.; Craig Leonardi, MD, St. Louis University School of Medicine; Andrea Wang, Deepa Lalla, Ph.D., Michael Woolley, Ph.D., Angelika Jahreis, MD, and Ralph Zitnik, MD, of Amgen.
Source: Duke Universtiy School of Medicine
Did you know?
Etanercept (trade name Enbrel), approved for treating rheumatoid arthritis, effectively reduces not only the symptoms of the disease, but also depression and fatigue in psoriasis sufferers, according to a multi-university research team that includes a scientist at Duke University Medical Center. Etanercept, an antibody that blocks tumor necrosis factor-alpha, significantly improved the symptoms and depression associated with the disorder, the scientists reported in an article published online Dec. 14, 2005 by The Lancet.
Medicineworld.org: Arthritis Drug Effective for Depression
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.